Jeffrey Hessekiel Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Stock Performance

Shares of EXEL stock opened at $26.24 on Friday. Exelixis, Inc. has a 1 year low of $18.64 and a 1 year high of $27.83. The firm has a market capitalization of $7.48 billion, a PE ratio of 41.00, a price-to-earnings-growth ratio of 0.56 and a beta of 0.54. The stock has a fifty day moving average of $25.49 and a two-hundred day moving average of $23.45.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. The firm had revenue of $637.18 million during the quarter, compared to analyst estimates of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Equities research analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on EXEL shares. Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Exelixis in a research report on Tuesday, July 30th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Truist Financial reiterated a “buy” rating and set a $33.00 price objective (up previously from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $27.00 target price on shares of Exelixis in a report on Thursday. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.67.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EXEL. Farallon Capital Management LLC lifted its position in Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares during the period. Renaissance Technologies LLC raised its stake in shares of Exelixis by 0.4% in the 2nd quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock worth $340,714,000 after buying an additional 61,350 shares in the last quarter. LSV Asset Management raised its stake in shares of Exelixis by 107.7% in the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after buying an additional 2,989,021 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock valued at $115,434,000 after buying an additional 349,837 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after buying an additional 370,199 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.